Kim Papp1, Herve Bachelez2, Antonio Costanzo3, Peter Foley4, Melinda Gooderham5, Primal Kaur6, Joanna Narbutt7, Sandra Philipp8, Lynda Spelman9, Jolanta Weglowska10, Nan Zhang6, Bruce Strober11. 1. K Papp Clinical Research, Waterloo, Ontario, Canada; Probity Medical Research, Waterloo, Ontario, Canada. Electronic address: kapapp@probitymedical.com. 2. Sorbonne Paris Cité Université Paris Diderot, Department of Dermatology, Assistance Publique-Hopitaux de Paris Saint-Louis Hospital, Paris, France. 3. Dermatology Unit, Department of Neuroscience, Mental Health and Sensory Systems (NeSMOS) Department, Sapienza University of Rome, Rome, Italy. 4. Probity Medical Research, Carlton, Australia; Department of Medicine (Dermatology), University of Melbourne, St Vincent's Hospital Melbourne, Skin and Cancer Foundation Inc, Melbourne, Australia. 5. Probity Medical Research, Waterloo, Ontario, Canada; SKiN Centre for Dermatology, Peterborough, Ontario, Canada. 6. Amgen Inc, Thousand Oaks, California. 7. Dermoklinika Medical Centre, Lodz, Poland. 8. Psoriasis Research and Treatment Center, University Hospital Charité, Berlin, Germany. 9. Probity Medical Research, Woolloongabba, Australia; Veracity Clinical Research, Woolloongabba, Australia. 10. Regional Hospital, Department of Dermatology, Wroclaw, Poland. 11. Probity Medical Research, Farmington, Connecticut; University of Connecticut Health Center, Connecticut.
Abstract
BACKGROUND: ABP 501 is a biosimilar of adalimumab. OBJECTIVE: We sought to compare the efficacy and safety of ABP 501 with adalimumab. METHODS: This 52-week, double-blind study randomized patients with moderate to severe psoriasis to ABP 501 oradalimumab. At week 16, those with 50% or more improvement in Psoriasis Area and Severity Index score from baseline on ABP 501 continued the same treatment, whereas adalimumab-treated patients were rerandomized to adalimumab or ABP 501. Clinical similarity in Psoriasis Area and Severity Index percent improvement from baseline to week 16 (primary end point) was established if the point estimate of treatment difference and its 2-sided 95% confidence interval between groups was within equivalence margin of ±15. Patients, including those undergoing a single transition at week 16, were evaluated for safety and immunogenicity. RESULTS:Psoriasis Area and Severity Index percent improvement at week 16 was 80.9 for ABP 501 and 83.1 for adalimumab (least-square mean difference -2.18 [95% confidence interval -7.39 to 3.02]). Adverse events (67.2% [117/174] vs 63.6% [110/173]) and antidrug antibody incidence (55.2% [96/174] vs 63.6% [110/173]) for ABP 501 vs adalimumab were similar. Safety, including immunogenicity, was similar among groups after single transition (week 20). LIMITATIONS: The 52-week data are not reported here. CONCLUSIONS: ABP 501 was shown to be clinically similar to adalimumab. Safety and immunogenicity were not impacted immediately after single transition (adalimumab to ABP 501).
RCT Entities:
BACKGROUND:ABP 501 is a biosimilar of adalimumab. OBJECTIVE: We sought to compare the efficacy and safety of ABP 501 with adalimumab. METHODS: This 52-week, double-blind study randomized patients with moderate to severe psoriasis to ABP 501 or adalimumab. At week 16, those with 50% or more improvement in Psoriasis Area and Severity Index score from baseline on ABP 501 continued the same treatment, whereas adalimumab-treated patients were rerandomized to adalimumab or ABP 501. Clinical similarity in Psoriasis Area and Severity Index percent improvement from baseline to week 16 (primary end point) was established if the point estimate of treatment difference and its 2-sided 95% confidence interval between groups was within equivalence margin of ±15. Patients, including those undergoing a single transition at week 16, were evaluated for safety and immunogenicity. RESULTS:Psoriasis Area and Severity Index percent improvement at week 16 was 80.9 for ABP 501 and 83.1 for adalimumab (least-square mean difference -2.18 [95% confidence interval -7.39 to 3.02]). Adverse events (67.2% [117/174] vs 63.6% [110/173]) and antidrug antibody incidence (55.2% [96/174] vs 63.6% [110/173]) for ABP 501 vs adalimumab were similar. Safety, including immunogenicity, was similar among groups after single transition (week 20). LIMITATIONS: The 52-week data are not reported here. CONCLUSIONS:ABP 501 was shown to be clinically similar to adalimumab. Safety and immunogenicity were not impacted immediately after single transition (adalimumab to ABP 501).
Authors: Yanchen Zhou; Hweixian L Penny; Mark A Kroenke; Bianca Bautista; Kelly Hainline; Lynette S Chea; Jane Parnes; Daniel T Mytych Journal: J Immunother Cancer Date: 2022-04 Impact factor: 12.469
Authors: Hillel P Cohen; Andrew Blauvelt; Robert M Rifkin; Silvio Danese; Sameer B Gokhale; Gillian Woollett Journal: Drugs Date: 2018-03 Impact factor: 9.546
Authors: Ross A McKinnon; Matthew Cook; Winston Liauw; Mona Marabani; Ian C Marschner; Nicolle H Packer; Johannes B Prins Journal: BioDrugs Date: 2018-02 Impact factor: 5.807